干细胞
Post-PCI Selection of Antithrombotic Therapy
Post-PCI Selection of Antithrombotic Therapy Improvements in antithrombotic pharmacotherapy have led to important reductions in complications after percutaneous coronary intervention. By John P. Vavalle, 医学博士, and Robert A. Harrington, MD Since the introduction of percutaneous coronary intervention (PCI) 多于 3 decades ago, the rates of procedural success and associated 阅读更多…
干细胞疗法
氯吡格雷生物等效性研究样品.
氯吡格雷报价 75 平板电脑研究设计: 两期的, 交叉, 单剂量生物等效性研究 36 健康的男女志愿者, 临床隔离期间 10 几小时前和 32 服药后数小时, 20 将在给药前收集每个受试者每个时期的血液样本,直到 32 小时后 阅读更多…